Arginine/lysine not checked

Advanced Accelerator Applications

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“1000 milliliters (mL) administered at a constant rate of 250 mL per hour”In the company’s words, NCT04524442 on ClinicalTrials.gov
Tested for
Gastroenteropancreatic Neuroendocrine Tumors
Main trialPhase 4
“The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post start of infusion compared to baseline.”In the company’s words, NCT04524442 on ClinicalTrials.gov
Other names
LysaKare

Other drugs for Gastroenteropancreatic Neuroendocrine Tumors

All 8 drugs for Gastroenteropancreatic Neuroendocrine Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 4Completed 18 Nov 2023 Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Arginine/lysine

Following is part of Solo: you see every change to Arginine/lysine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in